The Cunningham Panel™
“The Cunningham Panel™” is a test package to aid the clinician’s diagnosis of PANS or PANDAS, it’s known as “The Cunningham Panel™” as it was Dr. Cunningham’s research that led to the establishment of the panel.
“The Cunningham Panel™” consists of 5 assays. The first 4 assays yield results that are expressed as a titer or final dilution at which an endpoint reaction was observed on an Enzyme-Linked Immunosorbent Assay (ELISA) format. These assays measure circulating levels of autoantibodies directed against specific neuronal antigens including: Dopamine D1 Receptor (DRD1), Dopamine D2L Receptor (DRD2L), Lysoganglioside – GM1, and Tubulin. The fifth assay, CaM Kinase II Activation, yields a laboratory value (expressed as a numeric score) that reflects the percent of baseline CaM Kinase II activity in a human neuronal cell line and is a part of the activation pathway for the production of dopamine. Identification of these autoimmune antibodies directed against specific neurologic receptors may assist the clinician in making an accurate and timely diagnosis.
“The Cunningham Panel™” is commercially available as a laboratory service by Wieslab (outside the United States) and Moleculera Labs (within the United States).
“The Cunningham Panel™” may be used to support the PANDAS/PANS diagnosis, which is often based on a set of defined clinical symptoms, and act as an aid in determining the root cause of the symptoms.
Autoantibodies have been associated with OCD (obsessive compulsive disorder), ticks, Tourette's syndrome, Sydenham Chorea, PANS (Pediatric Acute-onset Neuropsychiatric syndrome), and PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infection).
PANDAS has been described as presenting with an acute onset of OCD and/or motor tics in children with a recent streptococcal infection. PANS also includes other causes than the PANDAS syndrome. Symptoms include neurological symptoms that may be presented as ticks, dyskinesia, hyperactivity, obsessions and compulsions.
Pediatric Autoimmune Neuropsychiatric syndromes (PANS or PANDAS) (564)
Tests in package
Beta-tubulin antibodies, CaM kinase II activity, Dopamin receptor 1 antibodies, Dopamin receptor 2 antibodies, Lyso-GM1 antibodies
Wieslab’s test package to aid the clinician’s diagnosis of PANS or PANDAS consists of 5 individual tests combined in a panel. The test panel is also known as “The Cunningham Panel™” as it was Dr. Cunningham’s research that led to the establishment of the panel.